Boehringer Ingelheim announces the "PRRS European Research Award 2020"
Guadalajara, Mexico, April 17, 2020 - For the fifth year, the veterinary pharmaceutical company Boehringer Ingelheim Animal Health reaffirms its support for research in order to improve the control of the main diseases of the pig sector in the world, opening its call for the "European Award for PRRS Research 2020” .
The objective is to promote the study focused on the practical application of strategies for the control of Porcine Reproductive and Respiratory Syndrome (PRRS), the interaction between researchers and veterinarians, as well as to promote communication within the industry on practical strategies that prevent its appearance. on the farms.
It should be noted that PRRS virus disease infects pigs worldwide, causing respiratory tract illnesses in growing pigs and impaired reproductive performance in males and females.
Boehringer Ingelheim will provide three prizes of €25,000 each to fund these projects, which will generate new and relevant data to better understand this devastating and costly disease.
The deadline for receiving research proposals for the PRRS European Research Award 2020 ends on July 1, 2020 .
Research requests should be sent by email to paulina.hoerstermann@boehringer-ingelheim.com. You can find more information about the bases for the presentation on the official page: www.prrs.com .
An independent review committee will carefully evaluate each proposal and select it based on several factors, including relevance, potential for industry impact, originality, and innovation. Members of the review board are highly regarded professionals from the swine industry, including researchers and practitioners.
Finally, Francisco Escudero , Director of the Pork segment at Boehringer Ingelheim Animal Health in Mexico, acknowledged that the country has great weight within the industry, since one in every 100 tons of pork in the world is Mexican, with more than one million 500 thousand tons per year; Therefore, with these actions, Boehringer Ingelheim Animal Health highlights its commitment to producers and veterinarians so that production health and quality continue to be present at all times.
Boehringer Ingelheim's Animal Health business division is the second largest animal health company in the world, with net sales of €4 billion in 2019 and a presence in more than 150 markets. Around the world, our 10,000 employees create the future of animal welfare through their daily work. Respect for animals, people and the environment is at the heart of what we do. We believe in prevention over treatment and therefore focus on developing innovative solutions in the field of vaccines, parasiticides and therapeutics. We develop a broad portfolio of innovative digital products, services and technologies to protect animals from disease and pain. Also, we support our clients in caring for the health of their animals and protect our communities against diseases that threaten life and society. Boehringer Ingelheim stands for advanced prevention. For more information visit:https://www.boehringer-ingelheim.mx/veterinaria/salud-animal
Hacer medicamentos nuevos y mejores para humanos y animales es la esencia de lo que hacemos. Nuestra misión es crear terapias innovadoras que cambien vidas y prevengan enfermedades. Desde su fundación en 1885, Boehringer Ingelheim es independiente y de propiedad familiar. Son más de 51,000 empleados quienes crean valor a través de la innovación diariamente para nuestras tres áreas de negocios: Salud humana, Salud animal y Fabricación de biofarmacéuticos.
En 2019, Boehringer Ingelheim logró ventas netas de 19 mil millones de euros. Nuestra importante inversión de casi 3,500 millones de euros en I + D impulsa la innovación, permitiendo la próxima generación de medicamentos que salvan y mejoran la calidad de vida. Boehringer Ingelheim planea por generaciones y se enfoca en el éxito a largo plazo. Por lo tanto, la compañía apunta al crecimiento orgánico a partir de sus propios recursos con apertura simultánea a las asociaciones y alianzas estratégicas en investigación. Al trabajar juntos, aceleramos la entrega del próximo avance médico que transformará la vida de los pacientes ahora y en las generaciones venideras. Puede encontrar más información sobre Boehringer Ingelheim en nuestro sitio: www.boehringer-ingelheim.com o en nuestro informe anual: http://annualreport.boehringer-ingelheim.com.